Anserine, HClO-scavenger, protected against cognitive decline in individuals with mild cognitive impairment

Nobutaka Masuoka¹*, Chenxu Lei¹, Haowei Li³, Noriko Inamura²,³, Shigenobu Shiotani⁴, Nobuya Yanaï⁴, Kenichiro Sato⁴, Keisuke Sakurai⁴, Tatsuhiro Hisatsune¹

¹Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan
²Community Hearth Promotion Laboratory, Mitsui Fudosan, Co., Ltd., Kashiwa, Japan
³Urban Design Center Kashiwanoha (UDCK), Kashiwa, Japan
⁴Research Division, Tokai Bussan Co., Ltd., Tokyo, Japan
*Present address: Hojo Clinic, Shinagawa, Tokyo, Japan

Correspondence to: Tatsuhiro Hisatsune; email: hisatsune@edu.k.u-tokyo.ac.jp
Keywords: Alzheimer’s disease, mild cognitive impairment, myeloperoxidase, hypochlorous acid, anserine
Received: May 6, 2020   Accepted: December 18, 2020   Published: January 20, 2021

ABSTRACT

Neuroinflammation has been recognized as a promising target when considering strategies for treating AD. In particular, it has been shown that neutrophils and MPO-mediated neuroinflammatory responses with the production of HClO play a role in the progression of AD. In this study, we aimed to evaluate the effects of anserine, a scavenger of HClO, on the protection of cognitive declines in persons with MCI. Fifty-eight elderly volunteers were screened, and 36 MCI individuals were assigned either to an active arm, who received 500 mg anserine per day, or a placebo arm, for 12-weeks. To assess cognitive function, we performed MMSE at baseline and after the ingestion. The data of the MMSE for 30 subjects who completed the follow-up tests were analyzed. A significant difference was detected in the change score of MMSE between the active arm (1.9 ± 2.0; n = 15) and the placebo arm (0 ± 2.8; n = 15) (p = 0.036). After the correction with the daily intake of anserine, the significance was elevated (p = 0.0176). Our results suggest that anserine protects elderly persons with MCI from cognitive declines by suppressing MPO-mediated neuroinflammatory responses.

INTRODUCTION

By 2050, more than 130 million people are estimated to have dementia worldwide [1]. It is thought that there will be nearly 10 million new cases every year [2]. AD, the most frequent cause of dementia, is a neurodegenerative disease. In AD, the accumulation of cerebral amyloid-beta has usually been occurring for more than 20 years before the onset of dementia [3]. At the dementia stage, neuronal damage progresses together with the accumulation of tau protein [3]. The necessity of targeting preclinical or prodromal AD in clinical trials for preventing dementia due to AD is now widely recognized [4, 5]. However, no clear evidence of pharmacological treatments or daily life improvement for preventing the development of dementia has been demonstrated [6, 7].

In recent years, the role of neuroinflammation in the pathogenesis of AD has received attention [8–10]. In addition to cells in brain tissue, blood vessels and blood cells also have potent effects on neuroinflammation. The pursuit of drug targets other than the inhibition of senile plaques accumulation or neurodegeneration would be hoped [11]. The innate immune system contributes to neuroinflammation [9, 12, 13]. It has been shown that MPO-mediated inflammatory responses caused by the production of HClO radicals play a role in the progression of AD [14–18]. In AD patients, it has been confirmed that MPO expression increases in brain tissue
and it has also been reported that the MPO level increases in the blood [18]. In addition, in an Asian cohort study, MPO rs233327 polymorphism was positively associated with AD risk and MPO accumulation in the plasma [15]. Animal model studies have also provided evidence that MPO is involved in the development of AD. It has also been reported that MPO activity inhibition improves cognitive functions in the AD model mice [19, 20].

Anserine is among the molecular species called histidine-containing dipeptides [21–25]. They exist at high concentrations in the muscle of some vertebrate species and are known to have antioxidative activity toward HClO radicals [21, 26–28]. The beneficial effects of ACS on cognitive functions were demonstrated in previous trials, in which the test material derived from the chicken extract was used to provide the study subjects 1000 mg mixture of anserine and carnosine (approx. 3:1 weight ratio) per day, for 3-12 months [29–34]. It was shown that ACS suppressed cognitive decline in normal subjects [29–31, 33, 34] and might promote reversion to cognitive-normal in MCI subjects [32]. Carboxinosine, present in serum and brain, is thought to degrade carnosine quickly when orally taken [21, 35]. Therefore, we hypothesized that anserine would function as an active compound. In an animal model, anserine alone protects against cognitive decline in AD model mice [36]. In the present study, we conducted a randomized, double-blind, placebo-controlled trial in which the test substance was anserine, and the subjects were with MCI.

RESULTS

Study individuals

Of 58 participants, the conditions of 36 individuals were diagnosed as MCI, considering their history and presence at an interview with the assistance of a psychological test battery. Both the active arm and placebo arm registered 18 after randomization, as shown in Figure 1. Among them, 30 individuals completed the examinations at follow-up (15 in the active arm and 15 in the placebo arm). Table 1 shows the characteristics. All reported an ingestion rate of over 90% on their self adherence records. The amounts of anserine and carnosine intake from daily meals estimated from a dietary survey were found to be equivalents between the two arms.

Test formulae

The test formula for the active arm contains purified anserine (>93%) from salmon meat. The active arm's supplement consisted of anserine powder, dextrin, maltose, sweeteners (stevia and sucralose), flavor, vitamin C, citric acid, and ferulic acid. Table 2 shows the amounts contained in a package. The anserine in the active food was replaced by dextrin in the food in the

**Figure 1. Flow diagram showing the number of subjects during the study.** Baseline test: The test at the start of the intervention. Follow-up test: The test at twelve weeks after the start.
Table 1. Characteristics of the study subjects who completed the study at baseline.

|                         | Active group       | Placebo group      | p value |
|-------------------------|--------------------|--------------------|---------|
| Age                     | 74.5±4.6 a         | 72.0±5.2           | 0.17    |
| Gender (M/F)            | 11/4               | 8/7                | 0.26    |
| BMI                     | 21.9±2.2           | 21.4±2.1           | 0.49    |
| Years of education      | 15.4±2.5           | 15.0±1.9           | 0.62    |
| Daily anserine (mg)     | 335±55             | 368±42             | 0.71    |
| Daily carnosine (mg)    | 162±33             | 171±20             | 0.86    |

aAverage ± Standard Deviation.

Table 2. Test Formulae.

| Ingredient              | Active     | Placebo    |
|-------------------------|------------|------------|
| Anserine                | 250 mg     | 0 mg       |
| Ferulic Acid (FA)       | 15 mg      | 15 mg      |
| Vitamin C (VC)          | 75 mg      | 75 mg      |
| Citric Acid             | 200 mg     | 200 mg     |
| Maltose                 | 500 mg     | 500 mg     |
| Sweeteners              | 11 mg      | 11 mg      |
| Flavor                  | 7 mg       | 7 mg       |
| Dextrin                 | 942 mg     | 1192 mg    |
| Total                   | 2000 mg    | 2000 mg    |

placebo arm. The supplement provided for both arms was indistinguishable by sight, smell, or taste. In an antioxidant assay, anserine was shown to be a potent HClO scavenger. It specifically removed the toxicity of HClO (Figure 2). Ferulic acid scavenged the toxicity of OH radicals, and vitamin C did that of ONOO radicals. We provided two packages a day so that the active arm subjects would ingest 500 mg of anserine per day, 250 mg both in the morning and the evening.

Analysis of efficacy on cognitive functions in subjects

Table 3 shows the results of the MMSE. We detected a significant difference between the active arm and the
Table 3. MMSE psychometric test data for the participants who completed the trial.

|               | Baseline       | Follow-up      | Change (Time x Treatment) |
|---------------|----------------|----------------|---------------------------|
|               | Active | Placebo | Active | Placebo | Active | Placebo | p value |
| MMSE          | 25.5±2.1 | 26.9±2.8 | 27.3±1.8 | 26.9±3.0 | 1.8±2.0 | 0±2.5   | 0.036*  |

*p value less than 0.05 is shown by *.

placebo arm in the primary outcome, the change value of MMSE scores (Two-way repeated ANOVA (Time x Treatment), $F_{(1,28)} = 4.8462$, $p = 0.036$). As shown in Figure 3, no subject in the active arm deteriorated the score of MMSE. In the placebo arm, two subjects fell below the cutoff score for dementia (23/24) of MMSE, and both of them reported symptoms that did not contradict the onset of dementia. We did not detect any difference in the change score of ADAScog between the two arms ($p = 0.92$). The score change of the active arm was $-0.4 ± 3.2$, and that of the placebo arm was $-0.3 ± 2.6$. To evaluate the contribution of daily intake of anserine or carnosine to the score change of MMSE, we performed a multiple regression analysis (Table 4; regression variation, $p = 0.0014$). A negative effect of the daily anserine intake (partial regression coefficient = $-0.0109$, $p = 0.0209$) and a positive effect of the daily carnosine intake were found on the improvement of the MMSE scores in the twelve weeks of anserine supplementation. The greater benefit of anserine supplementation was suggested in individuals taking less anserine from daily meals.

**Clinical safety**

A participant in the active arm had felt like heatstroke before the tests at baseline and rescheduled the participation, then scarcely ingested the test food and dropped out due to dizziness in the way. Four participants, comprised of two in the active arm and two in the placebo arm, dropped out due to unknown reasons during the intervention. No cause-and-effect relationship about adverse effects was reported or suggested.

**Effect of anserine treatment on the blood CRP-level**

To investigate the mechanism of the anserine’s action in the brain, we tested fourteen elderly volunteers from the participants of the above-mentioned RCT for blood before and after the seven days of oral anserine supplementation. We noted a significant decrease in the blood CRP ($p = 0.036$, after the paired t-test). We did not observe significant differences in the level of MPO and the tau-P 181 after the anserine treatment (data not shown).

**Figure 3. The distribution of the MMSE scores change.** A dot shows the points of individual improvement. A bar shows the average in the placebo-administered subjects or the anserine-administered subjects and ± Standard Deviation.
Table 4. Multiple regression analysis of the change score of MMSE with the amount of anserine and carnosine.

| Variable          | Partial regression coefficient | Standard error | Standard partial regression coefficient | F value | t value | p value \(a\) |
|-------------------|--------------------------------|----------------|-----------------------------------------|---------|---------|---------------|
| Active/Placebo (1/0) | 1.5710                         | 0.6214         | 0.4426                                  | 6.3915  | 2.5281  | 0.0176*       |
| Anserine (mg/day)  | -0.0109                        | 0.0045         | -1.8426                                 | 6.0140  | -2.4524 | 0.0209*       |
| Carnosine (mg/day) | 0.0240                         | 0.0087         | 2.0279                                  | 7.5088  | 2.7402  | 0.0107*       |

\(a\) p value less than 0.05 is shown by*.

In an independent study, elderly volunteers ingested 750 mg of anserine and 250 mg of carnosine and provided us venous blood samples. The plasma samples obtained before, 20 min, 40 min, 60 min, 80 min, and 120 min after the ingestion were tested for the anserine and carnosine levels. The maximum anserine concentration was reached between 40 and 60 minutes, and the half-life of anserine's blood concentration was shown to be about an hour (Figure 4), while the transfer of carnosine from the digestive system to the blood was not detected. We investigated the relationship between anserine's blood concentration and the change value of the serum CRP in the subjects of the anserine administration for a week (Figure 5). A significant correlation was detected between the blood anserine level and the decrease in CRP level \(\Delta CRP = -0.004 \times (\text{plasma anserine concentration}) - 0.0665; n = 14, R^2 = 0.79, p < 0.05\).

**DISCUSSION**

In the present study, we have shown for the first time that the effect of anserine, a natural HClO-scavenger, on the cognitive function in persons with MCI. Previous studies from our laboratory and others showed that anserine/carnosine supplementation at a dose of 1000 mg per day (anserine 750mg and carnosine 250mg) helps preserve cognitive function and keeps brain blood flow [29–34]. In our last trial [32], MMSE was used to evaluate the effect of anserine supplementation at a dose of 750 mg per day for 12 weeks. In the present trial, a lower dose of the possible active compound, anserine, was challenged. As a result, we detected a significant improvement with anserine (500 mg/day), as the change in the MMSE scores was 1.8 ± 2.0 in the active arm, 0 ± 2.5 in the placebo arm. Besides, daily anserine intake was found to affect the benefit of anserine supplementation. Very recently, in the Hisayama cohort, Hata et al. have demonstrated an inverse correlation between the risk of dementia onset and the serum level of beta-alanine, a metabolite of anserine [37]. In line with these observations, Toh et al. have revealed that anserine's daily consumption has favorable cognitive effects, especially in the memory domain, in a meta-analysis [38]. Therefore, it can be reasonably postulated that oral anserine supplementation benefits elderly individuals with the risk of dementia.

Neuroinflammation in the pathogenesis of AD has been attracting attention [8–10]. We have demonstrated that imidazolidepeptides control microglia appearing near the damaged brain tissues and take part in regulating inflammatory responses in a transgenic AD mouse model [36, 39]. However, the mechanism of controlling

![Figure 4. The concentration of blood anserine after ingestion. Dots and bars show the average ± Standard Deviation.](image1)

![Figure 5. The concentration of blood CRP (C-Reactive Protein) after the anserine treatment. Dots show the data of the individuals. Bars show the average ± Standard Deviation.](image2)
microglia had been unresolved. In a transgenic AD mouse model, it was well shown that the innate immune system, including neutrophils, contributes to the neuroinflammation and the memory decline in the AD mice [40, 41]. Zenaro et al. have reported that neutrophils adhered to vascular walls and enter brain tissue toward the senile plaques in the brain of AD model mice and AD patients. They found the accumulation of MPO around neutrophil extracellular traps (NETs) in the brain of AD model mice and AD patients. Very interestingly, they also demonstrated that the administration of antibodies against LFA-1, a molecule involved in the adsorption of neutrophils to the vascular walls, reduced the accumulation of senile plaques in brain tissue, subsided the activation of microglia, and improved memory function in the AD model mice [40]. Recently, Cruz Hernández et al. have reported transient clogging of micro-capillaries observed in AD model mouse brain through two-photon live imaging. Neutrophils, in collaboration with erythrocytes and platelets, were involved in this clogging. The administration of antibodies for one of the neutrophils' surface markers, Ly6g, improved the clogging and memory function shortly [41].

The facts of cognitive improvement by suppressing MPO activity in AD model mice considered together [19, 20], reasonable speculation could be that in the progression of AD, neutrophils adhere to neurovascular walls to release MPO, and MPO produces HClO radicals to generate neuroinflammation. In our previous studies, carnosine supplementation recovered the blood-vessel abnormality in these mice [39]. Anserine supplementation in AD model mice significantly prevented damage in brain microvascular pericytes [36]. Anserine has specific antioxidative activity against HClO radicals [42], as shown in Figure 2. In our previous study utilizing an MRI method, Arterial Spin Labeling (ASL), the ingestion of imidazole dipeptides for 3-12 months improved cerebral blood flow in the healthy elderly subjects [29, 30]. It has also been suggested that erythrocytes [43-45] or platelets [46] take in anserine, though the anserine level in the plasma just transiently increases after every oral intake [47, 48]. In our preliminary test of 1000 mg anserine supplementation per day with four adult healthy volunteers, the elevation of anserine concentration in platelets was observed by a high-spec LCmsms method, 45 min after the ingestion (CL, HL, TH; unpublished observation). Besides, several reports are suggesting that neutrophils take in imidazole dipeptides, anserine and carnosine, through PEPT2 [49], which transports the ligand of Nucleotide-binding Oligomerization Domain (NOD) receptor such as MurNac-L-Ala-D-isoGlu (MDP) [50-52]. There are also a series of reports showing that imidazole dipeptides repel the toxicity of HClO generated by MPO [21, 42, 45, 53]. Therefore, we could reasonably speculate as follows; neutrophils, erythrocytes, or platelets take in anserine, then the anserine in these blood cells scavenges the HClO radicals produced by MPO from neutrophils in the brain capillaries, thereby suppressing blood flow stagnation to protect cognitive functions.

In line with our findings on anserine for AD, Peters et al. have very recently demonstrated that anserine ameliorated diabetic nephropathy and halved proteinuria in diabetic mice (db/db) [54]. They also reported that anserine has more vigorous antioxidative activity than carnosine [54, 55], which was consistent with the treatments for diabetic nephropathy with carnosine or its derivative [56-58]. In addition to AD and diabetes, imidazole dipeptides exert antioxidative effects against inflammation in various diseases such as renal nephropathy, retinal degeneration, or pneumonia [21, 59]. Their pathogenesis involves neutrophil-mediated MPO activities [60, 61]. Our pilot monitoring for the present trial revealed statistically significant improvement in the blood creatinine level among the ten healthy adult volunteers administered 500 mg of the anserine supplementation every day for 12 weeks (data not shown). It suggested a potential effect of anserine on renal microvasculature. Also, virus-induced acute lung injury and MPO-mediated septic shock were relieved with imidazole dipeptides in rodent models [62-64]. Evidence of anserine against acute or chronic inflammation may support the notion that oral anserine intake is useful for protecting against the harm of endogenous HClO.

In this communication, we have proposed that daily intake of anserine supplementation at a dose of 500 mg per day helps preserve cognitive functions in elderly individuals with MCI by suppressing HClO radicals’ actions. There may be some complementary beneficial effects by the additives adopted, vitamin c or ferulic acids, to reinforce the inhibition of MPO-HClO-mediated inflammation by anserine. There are reports that both vitamin c and ferulic acid provide favorable effects for AD patients [65-68]. Their antioxidative activity against HClO may synergize with anserine since vitamin c removes ONOO- radicals and ferulic acids do HO-radicals (Figure 2).

Accordingly, in the brain of elderly individuals who may be apt to aggravate cognitive declines due to AD, the production of HClO radicals from NETs in the brain parenchyma surrounding senile plaques presumably damages not only astrocytes but also microglia to promote neuroinflammation. Before the penetration of neutrophils into the affected brain parenchyma, anserine in the intracellular spaces of neutrophils, platelets, and erythrocytes in the brain micro-capillaries may remove
the harmful effect of HClO [69–72]. This study proposes the molecular strategy to control MPO-HClO-NETs cascade, leading to brain micro-capillaries’ damage and the cognitive declines associated with AD dementia, by a natural antioxidant, anserine, that is a potent scavenger for HClO radicals.

Limitations

In this study, the subject individuals were selected utilizing a cutoff value of the MoCA test [73], which is often used as a reference to diagnose MCI. However, we did not thoroughly examine the subtypes of MCI. There is a lack of experimental data regarding the incorporation of anserine into neutrophils after oral intake. In the present study, the efficacy of anserine was examined in three months. We would like to know how long this beneficial effect on cognitive functions will last. Long-term observation is awaited.

CONCLUDING REMARKS

In this communication, we noted that anserine has a cognitive improvement effect in persons with MCI, probably through a mechanism in which anserine scavenges HClO radicals generated by MPO released from neutrophils in the brain microcapillaries.

MATERIALS AND METHODS

Study design

This study is a randomized, double-blind, placebo-controlled trial conducted to evaluate anserine’s effects on community-dwelling individuals with MCI and in generally healthy physical condition. This study was approved by the Ethics Committee of The University of Tokyo (ID 17-218). This study was registered in the UMIN Clinical Trials Registry (UMIN000032319). The protocol of this study was in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human subjects. The participants were enrolled in the present trial by a responsible doctor. The randomizing allocation was planned to include equal numbers of subjects in the active arm and the placebo arm. To detect 1.5 point difference for the MMSE score with a type1 error protection of 0.05 and 80 % of power assuming a standard deviation (SD) of 1.5 from the results of the previous studies [32, 74], we performed a calculation to get a result that the number of necessary subjects in the present trial was 30. All of the study subjects and the clinical staff were blinded about the allocation through the follow-up test. The assignment to the two arms was performed by a third party (Imepro Inc., Tokyo, Japan), who also delivered the test formula to the participants.

Participants

The present trial included 12 weeks for intervention that started in July 2018. The study participants were expected to be generally healthy and not demented. They walked to the cognitive testing site in the suburb of the Tokyo Metro Area. We invited some of the present trial participants because they had scored 25 or less on the Montreal cognitive assessment (MoCA) [73], more than a month previously. All the participants received a detailed explanation of the present study’s purpose and procedure and provided written informed consent. The inclusion criteria were as follows: (1) the MoCA score is 25 or less at baseline [73], (2) a responsible doctor contradicted the diagnosis of dementia. The exclusion criteria were as follows: (1) acute or sub-acute illness of local brain lesion due to head injury, brain ischemia, or brain tumor, (2) the usage of donepezil, galantamine, rivastigmine, memantine, or imidazole dipeptides in the previous six months, (3) a history of a severe psychiatric illness or any obvious symptom or sign of psychiatric disorder at present, (4) the use of psychopharmaceuticals at present, other than sleep medication in the night, (5) allergy to salmon, (6) inability to walk to the test site, (7) participation or a plan to participate in another trial, (8) judgment of inadequacy to enroll by a responsible doctor [32].

Inventory of anserine and carnosine in the everyday diet

A dietary survey was conducted using a semi-quantitative method reported elsewhere to estimate anserine and carnosine intake from the usual diet, as described previously [32]. At the baseline and follow-up, participants filled out a self-administered questionnaire on the frequency of animal meat (chicken, pork, and beef) or fish (divided into salmon, red-meat fish represented by tuna, white fish, blue-back fish represented by mackerel, and eel) in their diet during the previous 12 weeks.

Test formula

We started by considering the effects of imidazoledipeptides ingestion on their blood concentration. In an independent assay, elderly volunteers ingested 750 mg of anserine and 250 mg of carnosine. We sampled the plasma of venous blood before and after the ingestion. The plasma was deproteinized with trichloroacetic acid (final concentration 5%) and filtered through a 0.45 μm filter to prepare HPLC samples. The method by Dunnett and Harris was partially modified and applied to quantify histidine-related compounds [75]. Carnosine was hardly absorbed into the vascular system or rapidly disappeared from the blood after ingestion comparatively to anserine, described in Figure 4.
Therefore, we tried to prepare a test food that includes anserine only as an imidazolinedipeptide for planning the present trial. Salmon was chosen as the raw material as it is free of carnosine, but abundant in anserine [21]. Purification of the processed material through a cation-exchanger and nano-filtration unit, utilized in the previous study [32], enabled us to remove creatinine, as well as odors specific to fish products, from anserine powder. For evaluating antioxidative activities toward radicals, HClO radicals were prepared by diluting sodium hypochlorite solution with Dulbecco’s buffered saline pH 7.2 (Wako). OH radicals were prepared just before the protein degradation assay by modification of the Fenton reaction. Briefly, 1ml of 130mM H₂O₂ was added to 100 μl each of 100mM EDTA, 100mM FeCl₃ - 2H₂O. ONOO radicals were prepared by the quench reactor method, as described before [42]. For protein degradation assay to evaluate the antioxidative activities of each ingredient, egg white protein (Ovalbumin, Sigma Chemicals, St. Louis, MO) dissolved in buffered saline at a concentration of 2.5 mg/ml was used as the target protein. A 200-μl aliquot of protein solution was placed in a 1-ml centrifugal tube and mixed with 25μl of the solution containing each antioxidant. The final concentrations of the active ingredients were 5mM for anserine (Ans) and vitamin C (VC), and 0.5mM for ferulic acid (FA).

Cognitive tests
To evaluate the cognitive function of participants, we utilized MMSE as a primary neuropsychological test. We obtained MMSE scores from every subject before and after the intervention period. We also obtained ADAS scores [30] to evaluate cognitive declines' progression related to dementia to apply the exclusion criteria.

Safety evaluation
In the previous randomized controlled trial conducted for 12 weeks with MCI individuals [32], we observed no adverse effect considered to have a cause-and-effect relationship with anserine administration of more than 500 mg per day. Besides, we have preliminarily monitored ten healthy adult volunteers who ingested the active supplement containing 500 mg of anserine, the same amount as in the present trial, every day for 12 weeks. There was no adverse effect or significant exacerbation in the items of blood biochemistry tests. In the present study, a responsible doctor interviewed the individuals who came to the follow-up test concerning any symptoms they could have.

Statistical analysis
To examine the effects of anserine supplementation on cognitive function, we performed a two-way repeated ANOVA (Time [baseline or follow-up] x Treatment [the active (anserine) or placebo]. A p value of less than 0.05 was defined as statistically significant. Data are shown as mean ± standard deviation (SD).

Ethics approval and consent to participate
The study was approved by the Local Medical Ethics Committees (The University of Tokyo, Tokyo, Japan).

Human and animal rights
All human procedures followed the Helsinki Declaration of 1975. No animals were used for this study.

Author disclosures
Dr. Yanai, Mr. Shiotani, and Mr. Sato are employees of Tokai Bussan Co. Ms. Inamura is an employee of Mitsui Fudosan Co. Dr. Hisatsune reports grant support from Tokai Bussan Co. during the study. Authors not named here have disclosed no conflicts of interest.

Consent for publication
All patients provided written informed consent for their data to be used for research purposes.

Abbreviations
AD: Alzheimer’s disease; MPO: Myeloperoxidase; HClO: Hypochlorous acid; MMSE: Mini-Mental State Examination; MCI: Mild cognitive impairment; ACS: Anserine/carnosine supplementation.

AUTHOR CONTRIBUTIONS
Guarantor of integrity of the entire study, TH; study concepts and study design, NM and TH; anserine purification from salmon and formulae preparation, SS, NY, and KenS; data acquisition, SS, NM, LC, LH, KeiS and NI; data analysis, NM and TH; literature research, NM and TH; statistical analysis, NM and TH; manuscript preparation, NM, NY, and TH; approval of the final manuscript, all authors.

ACKNOWLEDGMENTS
We would like to thank Editage (https://www.editage.com) for English language editing.

CONFLICTS OF INTEREST
The authors declare a conflicts of interest in the AUTHOR CONTRIBUTIONS and FUNDING sections.
FUNDING

This study was financially supported by a JSPS Grant-in-Aid for Scientific Research (Grant No. 25115004) and by Tokai Bussan Co. to T. H.

REFERENCES

1. World Health Organization. Towards a dementia plan: a WHO guide. 2018. https://apps.who.int/iris/bitstream/handle/10665/272642/9789241514132-eng.pdf

2. Alzheimer's Association. 2012 Alzheimer's disease facts and figures. Alzheimers Dement. 2012; 8:131–68. https://doi.org/10.1016/j.jalz.2012.02.001 PMID:22404854

3. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, et al, and Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292–323. https://doi.org/10.1016/j.jalz.2016.02.002 PMID:27012484

4. Loera-Valencia R, Cedezo-Minguez A, Kenigsberg PA, Page G, Duarte AI, Giusti P, Zuso M, Robert P, Frisoni GB, Cattaneo A, Zille M, Boltje J, Cartier N, et al. Current and emerging avenues for Alzheimer’s disease drug targets. J Intern Med. 2019; 286:398–437. https://doi.org/10.1111/joim.12959 PMID:31286586

5. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011; 7:280–92. https://doi.org/10.1016/j.jalz.2011.03.003 PMID:21514248

6. Butler M, McCrerey E, Nelson VA, Desai P, Ratner E, Fink HA, Hemmy LS, McCarten JR, Barclay TR, Brasure M, Davila H, Kane RL. Does cognitive training prevent cognitive decline?: a systematic review. Ann Intern Med. 2018; 168:63–68. https://doi.org/10.7326/M17-1531 PMID:29255842

7. Fink HA, Jutkowitz E, McCarten JR, Hemmy LS, Butler M, Davila H, Ratner E, Calvert C, Barclay TR, Brasure M, Nelson VA, Kane RL. Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review. Ann Intern Med. 2018; 168:39–51. https://doi.org/10.7326/M17-1529 PMID:29255847

8. Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer’s disease. Nat Immunol. 2015; 16:229–36. https://doi.org/10.1038/ni.3102 PMID:25689443

9. Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Nat Rev Immunol. 2018; 18:759–72. https://doi.org/10.1038/s41577-018-0051-1 PMID:30140051

10. Tejera D, Heneka MT. Microglia in Alzheimer’s disease: the good, the bad and the ugly. Curr Alzheimer Res. 2016; 13:370–80. https://doi.org/10.2174/1567205013666151116125012

11. Butler M, Nelson VA, Davila H, Ratner E, Fink HA, Hemmy LS, McCarten JR, Barclay TR, Brasure M, Kane RL. Over-the-counter supplement interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Ann Intern Med. 2018; 168:52–62. https://doi.org/10.7326/M17-1530 PMID:29255909

12. Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecerker A, Schwartz S, Albasset S, McManus RM, Tejera D, Griepe A, Santarelli F, Broserson F, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019; 575:669–73. https://doi.org/10.1038/s41586-019-1769-z PMID:31748742

13. Liu Y, Aguzzi A. Immunotherapy for neurodegeneration? Science. 2019; 364:130–31. https://doi.org/10.1126/science.aaw0685 PMID:30975878

14. Gellhaa S, Sunnemark D, Eriksson H, Olson L, Galter D. Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson’s and Alzheimer’s disease. Cell Tissue Res. 2017; 369:445–54. https://doi.org/10.1007/s00441-017-2626-8 PMID:28466093

15. Ji W, Zhang Y. The association of MPO gene promoter polymorphisms with Alzheimer’s disease risk in Chinese Han population. Oncotarget. 2017; 8:107870–76. https://doi.org/10.18632/oncotarget.22330 PMID:29296208

16. Reynolds WF, Hiltunen M, Pirskanen M, Mannermaa A, Helisalmi S, Lehtovirta M, Alafuzzoff I, Soininen H. MPO and APOEpsilon4 polymorphisms interact to increase risk for AD in finnish males. Neurology. 2000; 55:1284–90.
17. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA, Masliah E. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer’s disease. Exp Neurol. 1999; 155:31–41. 
https://doi.org/10.1006/exnr.1998.6977
PMID: 9918702

18. Tzikas S, Schlak D, Sopova K, Gatsiou A, Stakos D, Stamatelopoulos K, Stellos K, Laske C. Increased myeloperoxidase plasma levels in patients with Alzheimer’s disease. J Alzheimers Dis. 2014; 39:557–64. 
https://doi.org/10.3233/JAD-131469
PMID: 24217274

19. Maki RA, Tyurin VA, Lyon RC, Hamilton RL, DeKosky ST, Kagan VE, Reynolds WF. Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease. J Biol Chem. 2009; 284:3158–69. 
https://doi.org/10.1074/jbc.M807731200
PMID: 19059911

20. Volkman R, Ben-Zur T, Kahana A, Garty BZ, Offen D. Myeloperoxidase deficiency inhibits cognitive decline in the SXFAD mouse model of Alzheimer’s disease. Front Neurosci. 2019; 13:990. 
https://doi.org/10.3389/fnins.2019.00990
PMID: 31611761

21. Boldyrev AA, Aldini G, Derave W. Physiology and pathophysiology of carnosine. Physiol Rev. 2013; 93:1803–45. 
https://doi.org/10.1152/physrev.00039.2012
PMID: 24137022

22. Davey CL. An ion exchange method of determining carnosine, anserine and their precursors in animal tissue. Nature. 1957; 179:209–10. 
https://doi.org/10.1038/179209a0
PMID: 13400146

23. Smith EB. Anserine in muscle: possibility of determination by titration. Nature. 1939; 144:1015. 
https://doi.org/10.1038/1441015a0

24. Winnick T, Winnick RE. Pathways and the physiological site of anserine formation. Nature. 1959; 183:1466–68. 
https://doi.org/10.1038/1831466a0
PMID: 13657174

25. Zapp JA, Wilson DW. Quantitative studies of carnosine and anserine in mammalian muscle: I. A method for the determination of carnosine and anserine. J Biol Chem. 1938; 126:9–18. 
https://www.jbc.org/content/126/1/9.short

26. Karton A, O'Reilly RJ, Pattison DI, Davies MJ, Radom L. Computational design of effective, bioinspired HOCl antioxidants: the role of intramolecular Cl+ and H+ shifts. J Am Chem Soc. 2012; 134:19240–45. 
https://doi.org/10.1021/ja309273n

PMID: 23148773

27. Mao GJ, Liang ZZ, Bi J, Zhang H, Meng HM, Su L, Gong YJ, Feng S, Zhang G. A near-infrared fluorescent probe based on photostable Si-rhodamine for imaging hypochlorous acid during lysosome-involved inflammatory response. Anal Chim Acta. 2019; 1048:143–53. 
https://doi.org/10.1016/j.aca.2018.10.014
PMID: 30598144

28. Pattison DI, Davies MJ. Evidence for rapid inter- and intramolecular chlorine transfer reactions of histamine and carnosine chloramines: implications for the prevention of hypochlorous-acid-mediated damage. Biochemistry. 2006; 45:8152–62. 
https://doi.org/10.1021/bi060348s
PMID: 16800640

29. Ding Q, Tanigawa K, Kaneko J, Totsuka M, Katakura Y, Imabayashi E, Matsuda H, Hisatsune T. Anserine/carnosine supplementation preserves blood flow in the prefrontal brain of elderly people carrying APOE e4. Aging Dis. 2018; 9:334–45. 
https://doi.org/10.14336/AD.2017.0809
PMID: 29896423

30. Hisatsune T, Kaneko J, Kurashige H, Cao Y, Satsu H, Totsuka M, Katakura Y, Imabayashi E, Matsuda H. Effect of anserine/carnosine supplementation on verbal episodic memory in elderly people. J Alzheimers Dis. 2016; 50:149–59. 
https://doi.org/10.3233/JAD-150767
PMID: 26682691

31. Katakura Y, Totsuka M, Imabayashi E, Matsuda H, Hisatsune T. Anserine/carnosine supplementation suppresses the expression of the inflammatory chemokine CCL24 in peripheral blood mononuclear cells from elderly people. Nutrients. 2017; 9:1199. 
https://doi.org/10.3390/nu9111199
PMID: 29088099

32. Masuoka N, Yoshimine C, Hori M, Tanaka M, Asada T, Abe K, Hisatsune T. Effects of anserine/carnosine supplementation on mild cognitive impairment with APOE4. Nutrients. 2019; 11:1626. 
https://doi.org/10.3390/nu11071626
PMID: 31319510

33. Rokicki J, Li L, Imabayashi E, Kaneko J, Hisatsune T, Matsuda H. Daily carnosine and anserine supplementation alters verbal episodic memory and resting state network connectivity in healthy elderly adults. Front Aging Neurosci. 2015; 7:219. 
https://doi.org/10.3389/fnagi.2015.00219
PMID: 26640437

34. Szczesniak D, Budzeń S, Kopec W, Rymaszewska J. Anserine and carnosine supplementation in the elderly: effects on cognitive functioning and physical capacity. Arch Gerontol Geriatr. 2014; 59:485–90. 
https://doi.org/10.1016/j.archger.2014.04.008
41. Yanai N, Shiotani S, Hagiwara S, Nabetani H, Nakajima M. Antioxidant combination inhibits reactive oxygen species mediated damage. Biosci Biotechnol Biochem. 2008; 72:3100–6. 
https://doi.org/10.1271/bbb.80159
PMID: 19060409

42. Boldyrev A, Abe H. Metabolic transformation of neuropeptide carnosine modifies its biological activity. Cell Mol Neurobiol. 1999; 19:163–75. 
https://doi.org/10.1023/a:1006933028389
PMID: 10079975

43. Hipkiss A. Vulnerability of Human Erythrocytes to Persistent High Glycemic Index Diets: Implications for Ageing and Neurodegeneration: Possible Amelioration by Carnosine. J Aging Sci. 2019; 7:214. 
https://doi.org/10.35248/2329-8847.19.07.214

44. Lee B, Park JH, Lee YS, Cho MH. Carnosine and Related Compounds Protect Against HOCI-Induced Damage of Biomolecules. Toxicological Research. 1999; 15:109–15. 
http://www.koreascience.or.kr/article/JAKO199911919880836.page

45. Nikitenko NI, Shavratskiii VK, Boldyrev AA, Susliina ZA, Ionova VG. [Effect of carnosine and its derivatives on ADP-induced human platelet aggregation]. Vopr Med Khim. 1995; 41:41–43. 
PMID: 7771091

46. Everaert I, Baron G, Barbaresi S, Gilardoni E, Coppa C, Carini M, Vistoli G, Bex T, Stautemas J, Blancquaert L, Derave W, Aldini G, Regazzoni L. Development and validation of a sensitive LC-MS/MS assay for the quantification of anserine in human plasma and urine and its application to pharmacokinetic study. Amino Acids. 2019; 51:103–14. 
https://doi.org/10.1007/s00726-018-2663-y
PMID: 30302566

47. Yeum KJ, Orioli M, Regazzoni L, Carini M, Rasmussen H, Russell RM, Aldini G. Profiling histidine dipeptides in plasma and urine after ingesting beef, chicken or chicken broth in humans. Amino Acids. 2010; 38:847–58. 
https://doi.org/10.1007/s00726-009-0291-2
PMID: 19381778

48. Ekman AK, Cardell LO. The expression and function of nod-like receptors in neutrophils. Immunology. 2010; 130:55–63. 
https://doi.org/10.1111/j.1365-2567.2009.03212.x
PMID: 20002790

49. Hu Y, Song F, Jiang H, Nuñez G, Smith DE. SLC15A2 and SLC15A4 mediate the transport of bacterially derived Di/tripeptides to enhance the nucleotide-binding oligomerization domain-dependent immune response in mouse bone marrow-derived macrophages. J Immunol. 2018; 201:652–62.
51. Lénárt N, Brough D, Dénes Á. Inflammomasomes link vascular disease with neuroinflammation and brain disorders. J Cereb Blood Flow Metab. 2016; 36:1668–85. https://doi.org/10.1177/0271678X16662043 PMID: 27486046

52. Wolf AJ, Underhill DM. Peptidoglycan recognition by the innate immune system. Nat Rev Immunol. 2018; 18:243–54. https://doi.org/10.1038/nri.2017.136 PMID: 29292393

53. Tan KM, Candlish JK. Carnosine and anserine as modulators of neutrophil function. Clin Lab Haematol. 1998; 20:239–44. https://doi.org/10.1046/j.1365-2257.1998.00123.x PMID: 9777271

54. Kohan R, Yamamoto Y, Cundy KC, Ames BN. Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Proc Natl Acad Sci USA. 1988; 85:3175–79. https://doi.org/10.1073/pnas.85.9.3175 PMID: 3362866

55. Peters V, Calabrese V, Forsberg E, Volk N, Fleming T, Baelde H, Weigand T, Thiel C, Trovato A, Scuto M, Modafferi S, Schmitt CP. Protective actions of anserine under diabetic conditions. Int J Mol Sci. 2018; 19:2751. https://doi.org/10.3390/ijms19092751 PMID: 30217069

56. Albrecht T, Schliperoort M, Zhang S, Braun JD, Qiu J, Rodriguez A, Pastene DO, Krämer BK, Köppel H, Baelde H, de Heer E, Anna Altomare A, Regazzoni L, et al. Carnosine attenuates the development of both type 2 diabetes and diabetic nephropathy in BTBR ob/ob mice. Sci Rep. 2017; 7:44492. https://doi.org/10.1038/srep44492 PMID: 28281693

57. Menini S, Iacobini C, Ricci C, Scipioni A, Blasetti Fantauzzi C, Giacardi A, Salomone E, Canevotti R, Lapolla A, Orioli M, Aldini G, Pugliese G. D-carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a western diet through reduction of carbonyl stress and inflammation. Br J Pharmacol. 2012; 166:1344–56. https://doi.org/10.1111/j.1476-5381.2012.01834.x PMID: 22229552

58. Peters V, Schmitt CP, Zschocke J, Gross ML, Brismar K, Forsberg E. Carnosine treatment largely prevents alterations of renal carnosine metabolism in diabetic mice. Amino Acids. 2012; 42:2411–16. https://doi.org/10.1007/s00726-011-1046-4 PMID: 21833769

59. Derave W, De Courten B, Baba SP. An update on carnosine and anserine research. Amino Acids. 2019; 51:1–4. https://doi.org/10.1007/s00726-018-02689-9 PMID: 30617755

60. Aratani Y. Myeloperoxidase: its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys. 2018; 640:47–52. https://doi.org/10.1016/j.abb.2018.01.004 PMID: 29336940

61. Winterbourn CC, Kettle AJ, Hampton MB. Reactive oxygen species and neutrophil function. Annu Rev Biochem. 2016; 85:765–92. https://doi.org/10.1146/annurev-biochem-060815-014442 PMID: 27050287

62. Sun C, Wu Q, Zhang X, He Q, Zhao H. Mechanistic evaluation of the protective effect of carnosine on acute lung injury in sepsis rats. Pharmacology. 2017; 100:292–300. https://doi.org/10.1159/000479879 PMID: 28848223

63. Tanaka KI, Sugizaki T, Kanda Y, Tamura F, Niino T, Kawahara M. Preventive effects of carnosine on lipopolysaccharide-induced lung injury. Sci Rep. 2017; 7:42813. https://doi.org/10.1038/srep42813 PMID: 28205623

64. Xu T, Wang C, Zhang R, Xu M, Liu B, Wei D, Wang G, Tian S. Carnosine markedly ameliorates H9N2 swine influenza virus-induced acute lung injury. J Gen Virol. 2015; 96:2939–50. https://doi.org/10.1099/jgv.0.000238 PMID: 26233716

65. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC, and Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County study. Arch Neurol. 2004; 61:82–88. https://doi.org/10.1001/archneur.61.1.82 PMID: 14732624

66. Sgarbossa A, Giacomazza D, di Carlo M. Ferulic acid: a hope for Alzheimer’s disease therapy from plants. Nutrients. 2015; 7:5764–82. https://doi.org/10.3390/nu7075246 PMID: 26184304

67. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 2009; 7:65–74. https://doi.org/10.2174/157015909787602823 PMID: 19721819

68. Bowman GL. Ascorbic acid, cognitive function, and Alzheimer’s disease: a current review and future direction. Biofactors. 2012; 38:114–22. https://doi.org/10.1002/biof.1002 PMID: 22419527
69. Pietronigro EC, Della Bianca V, Zenaro E, Constantin G. NETosis in Alzheimer’s disease. Front Immunol. 2017; 8:211. https://doi.org/10.3389/fimmu.2017.00211 PMID:28303140

70. Gupta S, Kaplan MJ. The role of neutrophils and NETosis in autoimmune and renal diseases. Nat Rev Nephrol. 2016; 12:402–13. https://doi.org/10.1038/nrneph.2016.71 PMID:27241241

71. Piras IS, Bleul C, Talboom JS, De Both MD, Schrauwen I, Halliday G, Myers AJ, Serrano GE, Beach TG, Huentelman MJ. ESHRD: deconvolution of brain homogenate RNA expression data to identify cell-type-specific alterations in Alzheimer’s disease. Aging (Albany NY). 2020; 12:4124–62. https://doi.org/10.18632/aging.102840 PMID:32125278

72. Liebner S, Dijkhuizen RM, Reiss Y, Plate KH, Agalliu D, Constantin G. Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathol. 2018; 135:311–36. https://doi.org/10.1007/s00401-018-1815-1 PMID:29411111

73. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53:695–99. https://doi.org/10.1111/j.1532-5415.2005.53221.x PMID:15817019

74. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA. Modelling mini mental state examination changes in Alzheimer’s disease. Stat Med. 2000; 19:1607–16. https://doi.org/10.1002/(sici)1097-0258(20000615/30)19:11/12<1607::aid-sim449>3.0.co;2-o PMID:10844722

75. Dunnett M, Harris RC. Determination of carnosine and other biogenic imidazoles in equine plasma by isocratic reversed-phase ion-pair high-performance liquid chromatography. J Chromatogr. 1992; 579:45–53. https://doi.org/10.1016/0021-9673(92)80361-s PMID:1447350